Interesting ImagesIncidental Detection of Urothelial Carcinoma on 18F-Fluciclovine PET/CTSurasi, Devaki Shilpa Sudha MD∗; Lu, Yang MD∗; Corn, Paul MD†; Pettaway, Curtis MD‡; Bathala, Tharakeswara MD§Author Information From the ∗Division of Diagnostic Imaging, Department of Nuclear Medicine †Department of Genitourinary Medical Oncology ‡Department of Urology §Division of Diagnostic Imaging, Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX. Received for publication June 6, 2020; revision accepted September 2, 2020. Conflicts of interest and sources of funding: none declared. Correspondence to: Devaki Shilpa Sudha Surasi, MD, Division of Diagnostic Imaging, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Unit 1483, Houston, TX. E-mail: [email protected]. Clinical Nuclear Medicine: February 2021 - Volume 46 - Issue 2 - p e114-e115 doi: 10.1097/RLU.0000000000003342 Buy Metrics Abstract 18F-Fluciclovine PET/CT has become a common diagnostic imaging study used in the evaluation of biochemical recurrence in prostate cancer since its approval in 2016. We present a case report of an 82-year-old man with history of both prostate and bladder cancer who presented for a fluciclovine study due to rising PSA levels. There was incidental detection of focal penile activity, and a subsequent urethral biopsy performed showed urothelial carcinoma, which was also seen on a subsequent MRI study. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.